Aull & Monroe Investment Management Corp Sells 490 Shares of Amgen Inc. (NASDAQ:AMGN)

Aull & Monroe Investment Management Corp trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 10,514 shares of the medical research company’s stock after selling 490 shares during the quarter. Amgen makes up approximately 1.4% of Aull & Monroe Investment Management Corp’s holdings, making the stock its 23rd largest position. Aull & Monroe Investment Management Corp’s holdings in Amgen were worth $2,740,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. State Street Corp raised its holdings in Amgen by 1.2% in the 3rd quarter. State Street Corp now owns 29,317,018 shares of the medical research company’s stock worth $9,446,236,000 after acquiring an additional 345,537 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Amgen by 25.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 13,205,604 shares of the medical research company’s stock worth $3,441,909,000 after purchasing an additional 2,672,975 shares during the period. Geode Capital Management LLC raised its holdings in Amgen by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 12,122,889 shares of the medical research company’s stock worth $3,893,771,000 after purchasing an additional 103,851 shares during the period. Janus Henderson Group PLC increased its stake in Amgen by 11.7% in the 3rd quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company’s stock worth $1,657,183,000 after buying an additional 538,545 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Amgen by 6.3% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 4,442,543 shares of the medical research company’s stock valued at $1,431,432,000 after purchasing an additional 264,396 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Transactions at Amgen

In other news, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the transaction, the executive vice president now owns 62,147 shares in the company, valued at $18,222,743.34. This represents a 12.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,341 shares of company stock worth $20,644,335. Insiders own 0.69% of the company’s stock.

Amgen Trading Up 1.4 %

Shares of AMGN stock opened at $316.57 on Thursday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62. The stock has a 50-day moving average of $283.80 and a 200-day moving average of $299.78. The stock has a market cap of $170.06 billion, a price-to-earnings ratio of 41.93, a PEG ratio of 2.63 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.01%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio is 126.09%.

Analysts Set New Price Targets

AMGN has been the subject of several analyst reports. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. Redburn Partners dropped their price objective on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Truist Financial decreased their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a research report on Wednesday, January 8th. Royal Bank of Canada restated an “outperform” rating and set a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Finally, Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $314.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.